• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

    185.96 +3.24 (+1.77%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Apr 24, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 527,083
    Open 181.57
    Bid (Size) 182.00 (100)
    Ask (Size) 188.00 (20,000)
    Prev. Close 182.72
    Today's Range 180.90 - 191.14
    52wk Range 96.09 - 191.50
    Shares Outstanding 47,190,970
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Is This Healthcare Stock a Millionaire Maker? ↗
    If it can establish itself as a leading biotech in the future, it might be. 
    Via The Motley Fool
    Topics Initial Public Offering Intellectual Property
    News headline image
    Axsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric Conditions
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    +4.1%
    +4.1%
    1 Month
    +14.9%
    +14.9%
    3 Month
    N/A
    N/A
    6 Month
    +43.5%
    +43.5%
    1 Year
    +76.4%
    +76.4%

    More News

    Read More
    News headline image
    Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now ↗
    Via The Motley Fool
    Axsome Therapeutics Inc (NASDAQ:AXSM) Reports Q4 2025 Results, Meeting Revenue Forecasts but Posting Wider Loss ↗
    Via Chartmill
    AXSOME THERAPEUTICS INC (NASDAQ:AXSM) Fits the Minervini Growth Momentum Strategy ↗
    Via Chartmill
    News headline image
    This New $7 Million Bet Targets a CNS Drug Maker With Phase 3 Trial Underway and 27% Stock Gain ↗
    Via The Motley Fool
    News headline image
    2 Under-the-Radar Stocks to Buy and Hold ↗
    Via The Motley Fool
    News headline image
    Axsome Therapeutics CEO Completes Planned $6 Million Options Sale Ahead of Pivotal FDA Decision ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Axsome Therapeutics to Participate in Upcoming Investor Conferences
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    The Great Rotation: Small-Cap Stocks Slay the Giants as Market Breadth Hits Record Highs
    Via MarketMinute
    Topics Economy Initial Public Offering
    News headline image
    Axsome Therapeutics Initiates CLARITY Phase 3 Trial of Solriamfetol in Adults with Major Depressive Disorder with Excessive Daytime Sleepiness Symptoms
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Axsome Therapeutics’ Q4 Numbers Beat Wall Street Expectations: Analyst Sees Over 23% Upside For Stock ↗
    Via Stocktwits
    Topics Artificial Intelligence
    News headline image
    Axsome Therapeutics (AXSM): A CNS Powerhouse at a Commercial Crossroad
    Via Finterra
    Topics Economy Initial Public Offering Intellectual Property
    News headline image
    Axsome (AXSM) Q4 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Axsome Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Got $10,000? Axsome Therapeutics Could Be a Mental‑Health Moonshot by 2036 ↗
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Axsome Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Alkem Laboratories Ltd.
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Should You Buy Axsome Therapeutics Stock Before Feb. 23? ↗
    Via The Motley Fool
    News headline image
    1 High-Flying Stock With More Upside Ahead ↗
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    The Great Rotation: Russell 2000’s Historic 15-Day Streak Marks a Seismic Shift in Market Leadership
    Via MarketMinute
    Topics Artificial Intelligence ETFs Economy
    News headline image
    AXSM Stock Rises After Analyst Hikes Price Target On Auvelity Drug Optimism ↗
    Via Stocktwits
    Topics Artificial Intelligence
    News headline image
    Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of Fibromyalgia
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue
    From Axsome Therapeutics, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Axsome Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Axsome Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Axsome Therapeutics, Inc. - Common Stock trade on?
    Axsome Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Axsome Therapeutics, Inc. - Common Stock?
    The ticker symbol for Axsome Therapeutics, Inc. - Common Stock is AXSM on the Nasdaq Stock Market
    What is the current price of Axsome Therapeutics, Inc. - Common Stock?
    The current price of Axsome Therapeutics, Inc. - Common Stock is 185.96
    When was Axsome Therapeutics, Inc. - Common Stock last traded?
    The last trade of Axsome Therapeutics, Inc. - Common Stock was at 04/24/26 04:00 PM ET
    What is the market capitalization of Axsome Therapeutics, Inc. - Common Stock?
    The market capitalization of Axsome Therapeutics, Inc. - Common Stock is 8.78B
    How many shares of Axsome Therapeutics, Inc. - Common Stock are outstanding?
    Axsome Therapeutics, Inc. - Common Stock has 9B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.